Review



ovcar3 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC ovcar3 cells
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Ovcar3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1266 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/bio_rxiv__64898__2026__04__25__720834-184-0-2?v=ATCC
    Average 99 stars, based on 1266 article reviews
    ovcar3 cells - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity"

    Article Title: Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity

    Journal: bioRxiv

    doi: 10.64898/2026.04.25.720834

    A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Figure Legend Snippet: A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.

    Techniques Used: Binding Assay, Fluorescence, In Vitro, Concentration Assay, Positive Control, Incubation, Negative Control, Standard Deviation



    Similar Products

    ovcar3 cells  (ATCC)
    99
    ATCC ovcar3 cells
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Ovcar3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/bio_rxiv__64898__2026__04__25__720834-184-0-2?v=ATCC
    Average 99 stars, based on 1 article reviews
    ovcar3 cells - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    nih ovcar 3 cells  (Korean Cell Line Bank)
    86
    Korean Cell Line Bank nih ovcar 3 cells
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Nih Ovcar 3 Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/pm42121901-71-0-9?v=Korean+Cell+Line+Bank
    Average 86 stars, based on 1 article reviews
    nih ovcar 3 cells - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    nih ovcar 3 cells  (ATCC)
    99
    ATCC nih ovcar 3 cells
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Nih Ovcar 3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/us12606634-2531-0-2?v=ATCC
    Average 99 stars, based on 1 article reviews
    nih ovcar 3 cells - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    ovarian cancer cell line  (ATCC)
    99
    ATCC ovarian cancer cell line
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Ovarian Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/us12606634-2628-16-26?v=ATCC
    Average 99 stars, based on 1 article reviews
    ovarian cancer cell line - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    ovarian cancer cells  (ATCC)
    99
    ATCC ovarian cancer cells
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Ovarian Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/bio_rxiv__64898__2026__04__07__716952-52-6-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    ovarian cancer cells - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    american type cell culture  (ATCC)
    99
    ATCC american type cell culture
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    American Type Cell Culture, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/bio_rxiv__64898__2026__04__01__715986-116-8-12?v=ATCC
    Average 99 stars, based on 1 article reviews
    american type cell culture - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    cancer cell lines  (ATCC)
    99
    ATCC cancer cell lines
    A) Quantification of Cetuximab, an IgG1 Ab, binding to <t>OVCAR3</t> cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.
    Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/pm41899831-40-16-28?v=ATCC
    Average 99 stars, based on 1 article reviews
    cancer cell lines - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    ovarian carcinoma cell line ovcar3  (ATCC)
    99
    ATCC ovarian carcinoma cell line ovcar3
    (a, b) NG uptake and apoptosis activation in <t>OVCAR3</t> cells following the administration of the (a) PAH-HA NGs and (b) PAH-PEG NGs. OVCAR3 cells were incubated for 24 h with medium (CTR) or the indicated Cy5-labeled NGs (0.1 mg/mL) with a 1:1 lys-NTA:His-Rhod molar ratio tag functionalization. At the end of incubation, NG engulfment and caspase-3/7 (Casp3/7) activation were analyzed by flow cytometry. The percentages of Cy5-positive cells and Casp3/7-positive cells were calculated. (c) OVCAR3 cells incubated for 24 h with culture medium (CTR) or the indicated Cy5-labeled NGs. At the end of incubation, the endocytosis of NGs was analyzed by confocal microscopy. Scale bar = 20 μm. Nuclei were stained with DAPI (blue). Relative intensity (RI) of Cy5-positive NGs was quantified in at least 51 cells. Data represent mean ± SEM of triplicate cultures. Statistical significance was determined by Student’s t test. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001, ns = not significant.
    Ovarian Carcinoma Cell Line Ovcar3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nih+ovcar+3+cells/pmc13073731-182-2-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    ovarian carcinoma cell line ovcar3 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.

    Journal: bioRxiv

    Article Title: Systems serology of responses against tumor antigens in ovarian cancer reveal disrupted Fc-mediated immunity

    doi: 10.64898/2026.04.25.720834

    Figure Lengend Snippet: A) Quantification of Cetuximab, an IgG1 Ab, binding to OVCAR3 cells as compared to patient TBAs by fluorescence. Cetuximab was incorporated at concentrations of 0.01–0.1 µg/mL. B) Quantification of Cetuximab binding to FcγRIIIa as compared to patient TBAs via fluorescence. C) Percent cytotoxicity of unmodified patient TBAs, quantified by an in vitro effector response assay (n=36). All patient TBAs were normalized to the same concentration. Cetuximab was used as a positive control (+). NK cells co-incubated with OVCAR3 cells alone functioned as the negative control (-). A purple bar indicates a patient that was evaluated in A) and B). Data are represented as average ± standard deviation. See also Figure S4.

    Article Snippet: OVCAR3 cells (ATCC HTB-161) were grown in complete growth media.

    Techniques: Binding Assay, Fluorescence, In Vitro, Concentration Assay, Positive Control, Incubation, Negative Control, Standard Deviation

    (a, b) NG uptake and apoptosis activation in OVCAR3 cells following the administration of the (a) PAH-HA NGs and (b) PAH-PEG NGs. OVCAR3 cells were incubated for 24 h with medium (CTR) or the indicated Cy5-labeled NGs (0.1 mg/mL) with a 1:1 lys-NTA:His-Rhod molar ratio tag functionalization. At the end of incubation, NG engulfment and caspase-3/7 (Casp3/7) activation were analyzed by flow cytometry. The percentages of Cy5-positive cells and Casp3/7-positive cells were calculated. (c) OVCAR3 cells incubated for 24 h with culture medium (CTR) or the indicated Cy5-labeled NGs. At the end of incubation, the endocytosis of NGs was analyzed by confocal microscopy. Scale bar = 20 μm. Nuclei were stained with DAPI (blue). Relative intensity (RI) of Cy5-positive NGs was quantified in at least 51 cells. Data represent mean ± SEM of triplicate cultures. Statistical significance was determined by Student’s t test. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001, ns = not significant.

    Journal: ACS Applied Nano Materials

    Article Title: Metal-Coordinated His-Tag Functionalization of Polymeric Nanogels for Therapeutic Applications

    doi: 10.1021/acsanm.5c05531

    Figure Lengend Snippet: (a, b) NG uptake and apoptosis activation in OVCAR3 cells following the administration of the (a) PAH-HA NGs and (b) PAH-PEG NGs. OVCAR3 cells were incubated for 24 h with medium (CTR) or the indicated Cy5-labeled NGs (0.1 mg/mL) with a 1:1 lys-NTA:His-Rhod molar ratio tag functionalization. At the end of incubation, NG engulfment and caspase-3/7 (Casp3/7) activation were analyzed by flow cytometry. The percentages of Cy5-positive cells and Casp3/7-positive cells were calculated. (c) OVCAR3 cells incubated for 24 h with culture medium (CTR) or the indicated Cy5-labeled NGs. At the end of incubation, the endocytosis of NGs was analyzed by confocal microscopy. Scale bar = 20 μm. Nuclei were stained with DAPI (blue). Relative intensity (RI) of Cy5-positive NGs was quantified in at least 51 cells. Data represent mean ± SEM of triplicate cultures. Statistical significance was determined by Student’s t test. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001, ns = not significant.

    Article Snippet: The human ovarian carcinoma cell line OVCAR3 (ATCC HTB-161) was obtained from the American Type Culture Collection (LGC Standards, Teddington, UK) and cultured in RPMI 1640 medium (1×), supplemented with GlutaMax Supplement (Cat# 61870036; Thermo Fisher Scientific), 20% fetal bovine serum (Cat# F524-500 ML; Merck KGaA), 10,000 U mL –1 penicillin, and 10 mg/mL streptomycin.

    Techniques: Activation Assay, Incubation, Labeling, Flow Cytometry, Confocal Microscopy, Staining